Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC).
Marijo BilusicSheri McMahonRavi A MadanFatima KarzaiYo-Ting TsaiRenee N DonahueClaudia PalenaCaroline JochemsJennifer L MartéCharalampos S FloudasJulius StraussJason RedmanHoussein Abdul SaterShahrooz RabizadehPatrick Soon-ShiongJeffrey SchlomJames L GulleyPublished in: Journal for immunotherapy of cancer (2021)
NCT03481816.